¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"peptide phi"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® peptide ÇÑ±Û ÆéƼµå
¼³¸í   
  µÎ °³ÀÌ»óÀÇ ¾Æ¹Ì³ë»ê ºÐÀÚ »çÀÌ¿¡¼­, ÇÑÂÊÀÇ ¾Æ¹Ì³ë±â¿Í ´Ù¸¥ ÂÊÀÇ Ä«¸£º¹½Ç±â°¡ ¹° ºÐÀÚ¸¦ ÀÒÀ¸¸é¼­ ÃàÇÕÇÏ¿© ÀÌ·ç´Â ¾Æ¹Ìµå °áÇվƹ̳ë»êÀÇ ¼ö°¡ 2, 3, ¡¦ ÀΠ°æ¿ì, °¢°¢ µðÆéƼµå, Æ®¸®ÆéƼµå, ¡¦µîÀ¸·Î ºÎ¸£¸ç, ¿©·¯ °³ÀÇ ¾Æ¹Ì³ë»êÀ¸·Î ±¸¼ºµÇ´Â °ÍÀ» ¿Ã¸®°íÆéƼµå, À̺¸´Ù Å« °ÍÀ» Æú¸®ÆéƼµå¶ó°í ÇÑ´Ù. Á÷¼â»óÀÇ °ÍÀÌ ¸¹Áö¸¸, È¯»ó ±¸Á¶¸¦ °®´Â ÆéƼµåµµ ÀÖ´Ù. ÀúºÐÀÚÀÇ ÆéƼµå´Â ¹°, »ê, ¾ËÄ®¸® µûÀ§¿¡ Àß ³ì°í ¾ËÄڿÿ¡´Â ³ìÁö ¾ÊÀ¸³ª, °íºÐÀÚÀÇ ÆéƼµå´Â ¹°¿¡ Àß ³ìÁö ¾Ê°í ´Ü¹éÁú°ú ¼ºÁúÀÌ ºñ½ÁÇÏ´Ù. ³úÇϼöüȣ¸£¸ó, ºê¶óµðŰ´Ñ µî°ú °°ÀÌ »ý¸®Àû±â´ÉÀÌ ÇöÀúÇÑ °ÍÀº »ý¸®È°¼ºÆéƼµå(bioactive peptide)¶ó°í ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • phi phenomenon
    ÆÄÀÌÇö»ó
  • atrial natriuretic peptide
    ½É¹æ³ªÆ®·ýÀÌ´¢ÆéƼµå
  • brain natriuretic peptide
    ³ú³ªÆ®·ýÀÌ´¢ÆéƼµå
  • calcitonin gene-related peptide
    Ä®½ÃÅä´ÑÀ¯ÀüÀÚ°ü·ÃÆéƼµå
  • gastrin-releasing peptide
    °¡½ºÆ®¸°À¯¸®ÆéƼµå
  • glucagon-like insulinotropic peptide
    ±Û·çÄ«°ïÀ¯»çÀν¶¸°ÀÚ±ØÆéÆ¼µå
  • glucagon-like peptide
    ±Û·çÄ«°ïÀ¯»çÆéƼµå
  • peptide
    ÆéƼµå
  • peptide bond
    ÆéƼµå°áÇÕ
  • peptide linkage
    ÆéƼµå°áÇÕ
  • signal peptide
    ½ÅÈ£ÆéƼµå
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • peptide
    ÆéƼµå
  • atrial natriuretic peptide
    ½É¹æ³ªÆ®·ýÀÌ´¢ÆéƼµå
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • phi phenomenon
    ÆÄÀÌÇö»ó
  • brain natriuretic peptide
    ³ú³ªÆ®·ýÀÌ´¢ÆéƼµå
  • peptide bond
    ÆÕƼµå°áÇÕ
  • gastrin-releasing peptide
    °¡½ºÆ®¸°À¯¸®ÆéƼµå
  • peptide linkage
    ÆéƼµå°áÇÕ
  • peptide
    ÆéƼµå
  • signal peptide
    ½ÅÈ£ÆéƼµå
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • phi phenomenon
    ÆÄÀÌÇö»ó
  • BNP=> brain natriuretic peptide
    ³ú ³ªÆ®·ý ÀÌ´¢ ÆéƼµå
  • GIP (Gastric inhibitory peptide)
    À§Àå¾ïÁ¦(êÖíóåäð¤) ÆéŸÀ̵å
  • GRP (Gastrin-releasing peptide)
    °¡½ºÆ®¸°-ºÐºñÆéÆÄÀ̵å
  • Gastric inhibitory peptide
    À§¾ïÁ¦(êÖåäð¤)È£¸£¸ó
  • Gastrin-releasing peptide
    °¡½ºÆ®¸°ºÐºñÆéŸÀ̵å
  • VIP : vasoactive intestinal peptide
    Ç÷°üÀÛ¿ë ¼ÒÀåÆéŸÀ̵å.
  • VIP = vasoactive intestinal (poly)peptide
    Ç÷°üÀۿ뼺 ÀåÆéƼµå
  • procollagen III peptide
    ÇÁ·ÎÄݶó°Õ III ÆéƼµå
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • phi phenomenon
    ÆÄÀÌÇö»ó
  • atrial natriuretic peptide
    ½É¹æ³ªÆ®·ýÀÌ´¢ÆéŸÀ̵å, ½É¹æ³ªÆ®·ýÀÌ´¢ÆéƼµå
  • brain gut peptide
    ³úÀå °üÆéƼµå.
  • brain gut peptide
    ³úÀå °üÆéƼµå.
  • brain gut peptide
    ³úÀå°üÆéƼµå
  • brain natriuretic peptide
    ³ú ³ªÆ®·ý ÀÌ´¢ ÆéƼµå
  • brain peptide
    ³úÆéƼµå.
  • c-peptide
    ¾¾-ÆéŸÀ̵å, ¾¾-ÆéƼµå
  • c-peptide
    c ÆéƼµå
  • c-peptide measurement
    c ÆéƼµåÃøÁ¤
  • calcitonin-gene related peptide
    Ä®½ÃÅä´ÑÀ¯ÀüÀÚ°ü·ÃÆéƼµå
  • endogenous opiate peptide
    ³»À缺 ¿ÀÇÇ¿¡ÀÌÆ® ÆéŸÀ̵å, ³»À缺 ¾ÆÆí¾ç ÆéŸ À̵å.
  • neuro-peptide
  • opioid peptide
    ¾ÆÆí¾çÆéƼµå<ÆéŸÀ̵å>.
  • opioid peptide
    ¾ÆÆíÀ¯»çÆéƼµå<ÆéŸÀ̵å>.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • phi angle
    ÆÄÀ̰¢(ÊÇ)
  • connecting peptide
    ¿¬°á(Ö§Ì¿) ÆéŸÀ̵å
  • C peptide
    C ÆéŸÀ̵å
  • cyclic peptide
    °í¸®ÆéŸÀ̵å
  • DFP peptide
    DEP ÆéŸÀ̵å
  • fast peptide liquid chromatography
    °í¼Ó(ÍÔáÜ) ÆéŸÀÌµå ¾×ü(äûô÷)Å©·Î¸¶Åä±×·¡ÇÇ
  • gastric inhibitory peptide
    À§(êÖ) ÀúÇØ(îÁúª) ÆéŸÀ̵å
  • leader peptide
    ¼±µµ(à»Óô) ÆéŸÀ̵å
  • leader sequence peptide
    ¼±µµ¼­¿­(à»ÓôßíÖª) ÆéŸÀ̵å
  • opioid peptide
    ¾ÆÆí°è(ͧ) ÆéŸÀ̵å
  • peptic peptide
    Æé½ÅºÐÇØ(ÝÂú°) ÆéŸÀ̵å
  • peptide
    ÆéŸÀ̵å
  • peptide antibiotic
    ÆéŸÀ̵å Ç×»ýÁ¦(ù÷ßæð¥)
  • peptide bond
    ÆéŸÀÌµå °áÇÕ(Ì¿ùê)
  • peptide hormone
    ÆéŸÀ̵å È£¸£¸ó
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
PHI passive hemagglutination inhibition; past history of illness; phosphohexose isomerase; physiological...
PhI Pharmacopoeia Internationalis
f Greek letter phi; magnetic flux; osmotic coefficient
C-Peptide Connecting Peptide
ERP early receptor potential; effective refractory period; elodoisin-related peptide; endoscopic retrogr...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
PHI Peptide Histidine Isoleucine
PHI Peptide Histidine Isoleucine amide
AM phi Alveolar macrophage
M phi Mononuclear phagocyte
M phi Mouse peritoneal macrophage
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • 9-amino acid peptide
    9-¾Æ¹Ì³ë»ê ÆéŸÀ̵å
  • brain peptide
    ³ú ÆéƼµå
  • corticotropin-like intermediate lobe peptide

    corticotropin-releasing factor (ºÎ½Å ÇÇÁú È£¸£¸ó À¯¸® ¿ä¼Ò, ºÎ½Å ÇÇÁú È£¸£¸ó À¯¸® ÀÎÀÚ

  • dynorphin-related peptide
    ´ÙÀ̳îÇÉ °ü·Ã ÆéƼµå
  • endogenous analgesic peptide system
    ³»¿ø¼º ÁøÅ뼺 ÆéƼµå°è
  • endogenous opiate peptide
    ³»Àμº ¾ÆÆí ÆéŸÀ̵å, ³»À缺 ¿ÀÇÇ¿¡ÀÌÆ® ÆÕŸÀ̵å, ³»À缺 ¾ÆÆí¾ç ÆéŸÀ̵å
  • multiple biologically active peptide fragment
    ´Ù¹ß¼º »ý¹°ÇÐÀû Ȱ¼º ÆéŸÀÌµå ºÐÀý
  • non-peptide transmitter
    ºñÆéƼµå Àü´Þ ¹°Áú
  • opioid peptide
    ¾ÆÆí¾ç ÆéƼµå, ¾ÆÆí¾ç ÆéŸÀ̵å
  • parathyroid hormone-related peptide
    ºÎ°©»ó¼± È£¸£¸ó ¿¬°ü ÆéŸÀ̵å
  • peptide
    ÆéŸÀ̵å, ÆéƼµå
    °¡¼öºÐÇØ¿¡ ÀÇÇÏ¿© À̺ÐÀÚ ÀÌ»óÀÇ ¾Æ¹Ì³ë»êÀ» ¸¸µå´Â ÀúºÐÀÚ È­ÇÕ¹°·Î¼­, ÀÎÁ¢ ¾Æ¹Ì³ë»êÀÇ NH2±â¿Í COOH±â·ÎºÎÅÍ Å»¼ö °áÇÕÀ» ÅëÇÏ¿© Çü¼ºµÈ´Ù.
  • peptide E
    ÆéƼµå E
  • peptide hormone
    ÆéƼµå È£¸£¸ó
  • precursor peptide
    Àü±¸ ÆéƼµå
  • proenkephalin peptide
    ÇÁ·Î ¿£ÄÉÆÈ¸° ÆéƼµå
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
peptide phi A 27-amino acid peptide with histidine at the n-terminal and isoleucine amide at the c-terminal. The exact amino acid composition of the peptide is species dependent. The peptide is secreted in the intestine, but is found in the nervous system, many organs, and in the majority of peripheral tissues. It has a wide range of biological actions, affecting the cardiovascular, gastrointestinal, respiratory, and central nervous systems.
(12 Dec 1998)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
bacteriophage phi 6 Virulent bacteriophage and sole member of the genus cystovirus that infects pseudomonas species. The virion has a segmented genome consisting of three pieces of doubled-stranded DNA and also contains a unique lipid-containing membrane.
(12 Dec 1998)
bacteriophage phi x 174 The type species of the genus microvirus. A prototype of the small virulent DNA coliphages, it is composed of a single strand of supercoiled circular DNA, which on infection, is converted to a double-stranded replicative form by a host enzyme.
(12 Dec 1998)
phi 1. The 21st letter of the Greek alphabet.
2. (&Phi;) Symbol for phenyl; potential energy; magnetic flux.
3. (&phi;) Symbol for plane angle; volume fraction; quantum yield; the dihedral angle of rotation about the N-Ca bond associated with a peptide bond.
(05 Mar 2000)
phi phenomenon An illusion of movement, which occurs by means of successive visual impressions at intervals of 1/15 to 1/20 sec; when an occluder is passed from one eye to the other while a small distant light is observed, the light seems to move with the occluder in exophoria, but in an opposite direction in oesophoria.
(05 Mar 2000)
phi X 174 <molecular biology> Bacteriophage of E. Coli with a single stranded DNA genome and an icosahedral shell. This was the first DNA phage to be fully sequenced: the genome consists of 10 genes, some of which are overlapping genes.
(18 Nov 1997)
alpha-aminoacyl-peptide hydrolases <enzyme> Registry number: EC 3.4.11.
(12 Dec 1998)
anionic neutrophil activating peptide <cytokine> A cytokine that activates neutrophils and attracts neutrophils and T-lymphocytes.
It is released by several cell types including monocytes, macrophages, T-lymphocytes, fibroblasts, endothelial cells, and keratinocytes by an inflammatory stimulus. Il-8 is a member of the beta-thromboglobulin superfamily and structurally related to platelet factor 4.
Acronym: IL-8
(12 Dec 1998)
antibiotics, peptide Antibiotics whose structure contains one or more peptides, usually cyclic. They are generally effective against gram-positive bacteria and act by inhibiting peptidoglycan synthesis in bacterial cell walls.
(12 Dec 1998)
atrial natriuretic peptide <hormone> This cardiac hormone (28 amino acid residues) regulates salt and water balance in body fluids and blood pressure, it has potential as a medication to treat heart and kidney failure and the buildup of excess fluid in tissue.
(09 Oct 1997)
bradykinin-potentiating peptide <chemical> 2-l-tryptophan-3-de-l-leucine-4-de-l-proline-8-l-glutamine bradykinin potentiator b. A synthetic nonapeptide with the sequence pyr-trp-pro-arg-pro-gln-ile-pro-pro, which is identical to that of the peptide from the venom of the snake, bothrops jararaca. It acts as an inhibitor of kininase II and angiotensin I and has been proposed as an antihypertensive agent.
Pharmacological action: angiotensin-converting enzyme inhibitors, antihypertensive agents.
Chemical name: Bradykinin potentiator B, 2-L-tryptophan-3-de-L-leucine-4-de-L-proline-8-L-glutamine-
(12 Dec 1998)
brain natriuretic peptide <hormone, protein> Brain peptide that induces diuresis, related to atrial natriuretic peptide.
(18 Nov 1997)
calcitonin gene-related peptide <protein> A second product transcribed from the calcitonin gene. Calcitonin gene related peptide is found in a number of tissues including nervous tissue. It is a vasodilator that may participate in the cutaneous triple response.
It is a neuropeptide of 37 amino acids with structural homology to salmon calcitonin. Co-localises with substance P in neurons. It occurs as a result of alternative processing of mRNA from the calcitonin gene.
The neuropeptide is widely distributed in neural tissue of the brain, gut, perivascular nerves, and other tissue. The peptide produces multiple biological effects and has both circulatory and neurotransmitter modes of action. In particular, it is a potent endogenous vasodilator.
Intracerebral administration leads to a rise in noradrenergic sympathetic outflow, a rise in blood pressure and a fall in gastric secretion.
Acronym: CGRP
(05 May 2002)
vasoactive intestinal peptide <gastroenterology, protein> Peptide of 28 amino acids, originally isolated from porcine intestine, but later found in the central nervous system where it acts as a neuropeptide and is released by specific interneurons. May also affect behaviour of cells of the immune system.
Acronym: VIP
(05 Jan 1998)
gastrin-releasing peptide <hormone> A regulatory peptide (27 amino acids) thought to be the mammalian equivalent of bombesin. It elicits gastrin release and regulates gastric acid secretion and motor function.
It causes bronchoconstriction and vasodilation in the respiratory tract and stimulates the growth and mitogenesis of cells in culture. Once released from nerves in the antrum of the stomach, the neuropeptide stimulates release of gastrin from the g cells.
Chemical name: Gastrin-releasing peptide
(12 Dec 1998)
receptors, calcitonin gene-related peptide Cell surface proteins that bind calcitonin gene-related peptide (cgrp) with high affinity and trigger intracellular changes which influence the behaviour of cells. Cgrp receptors are present in both the central nervous system and the periphery and are not the same as calcitonin receptors.
(12 Dec 1998)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 1 ÆäÀÌÁö: 1
  • Peptide PHI - »õâ A 27-amino acid peptide with histidine at the N-terminal and isoleucine amide at the C-terminal. The exact amino acid composition of the peptide is species dependent. The peptide is secreted in the intestine, but is found in the nervous system, many organs, and in the majority of peripheral tissues. It has a wide range of biological actions, affecting the cardiovascular, gastrointestinal, respiratory, and central nervous systems.
    Synonyms : Human PHI, PHM Neuropeptide, PHM-27, Peptide HI, Peptide Histidine Methionine, Peptide PHI-27, Peptide-Histidine-Isoleucinamide, Porcine Intestinal Heptacosapeptide, Pro-Vasoactive Intestinal Peptide, Heptacosapeptide, Porcine Intestinal, Neuropeptide, PHM
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • peptide
    ÆéŸÀ̵å;µÑ ÀÌ»óÀÇ ¾Æ¹Ì³ë»ê °áÇÕ¹°
  • Phi Beta Kappa
    ÆÄÀÌ.º£Å¸.Ä«ÆÄŬ·´
  • Phi Bete
    ÆÄÀÌ.º£Å¸.Ä«ÆÄ±Û·´ÀÇ È¸¿ø
  • phi
    ±×¸®½º¾î ¾ËÆÄºªÀÇ 21¹øÂ° ±ÛÀÚ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á